Promising New Treatment for Metastatic Breast Cancer

At the European Society for Medical Oncology (ESMO) 2023 Congress Aditya Bardia, MD, MPH, presented results from the TROPION-Breast01 trial, which is comparing a new antibody-drug conjugate, datopotamab-deruxtecan (dato-DXd), to doctors’ choice of chemotherapy for inoperable or metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy and also had been treated with chemotherapy.

Listen to the podcast to hear Dr. Bardia explain:

• what an antibody-drug conjugate is
• the design of the TROPION-Breast01 study and the first results
• dato-DXd side effects
• how dato-DXd might fit into the current treatment landscape for metastatic breast cancer